Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAX-10181 in advanced solid tumor
NCT04122339Phase 1Unknown
- Sponsor
- Guangzhou Zaiji Medical Technology
- Start
- Feb 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MAX-10181 in solid tumor, sponsored by Guangzhou Zaiji Medical Technology. Primary endpoints: Adverse events at 8 weeks, Maximum tolerated dose at 4 weeks and 1 more. Status: unknown.
02
Drugs
MAX-10181
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04122339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04122339.